Trial Profile
5-HT3 Antagonists (Antiemetics) and Cardiac Safety Using an Active Surveillance Approach
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Ondansetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting; Hyperemesis gravidarum; Postoperative nausea and vomiting
- Focus Adverse reactions
- 13 May 2021 Status changed from recruiting to completed.
- 02 Nov 2020 Planned End Date changed from 1 Jul 2020 to 1 Mar 2021.
- 02 Nov 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Mar 2021.